Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients | Zendy

Bertrand Dautzenberg | Zendy; Paola Castellani | Zendy; JL Pellegrin | Zendy; Daniel Vittecoq | Zendy; C. Truffot-Pernot | Zendy; Nicoletta Pirotta | Zendy; D Sassella | Zendy

Open Access

Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients

Author(s) -

Bertrand Dautzenberg,

Paola Castellani,

JL Pellegrin,

Daniel Vittecoq,

C. Truffot-Pernot,

Nicoletta Pirotta,

D Sassella

Publication year - 1996

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.40.7.1722

Subject(s) - rifabutin , bacteremia , placebo , medicine , mycobacterium avium intracellulare infection , antibiotics , antibacterial agent , microbiology and biotechnology , mycobacterium avium complex , mycobacterium , gastroenterology , immunology , biology , tuberculosis , pathology , clarithromycin , alternative medicine

Rifabutin, 600 mg/day, was compared with a placebo in the early treatment of culture-proven Mycobacterium avium bacteremia in patients with AIDS. Following 14 days' treatment, bacteriological success, defined as a negative culture or a reduction in the number of CFU of M. avium organisms per milliliter of blood by a factor of > or = 0.5 log from the baseline, was observed in 7 of 10 (70%) evaluable rifabutin patients and in 1 of 13 (8%) evaluable placebo patients (P = 0.002). Rifabutin is active against M. avium as a single agent and can make a significant contribution to combination regimens for the treatment of disseminated M. avium infection in AIDS patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research